Effects Of Walnut-Enriched Diet On Blood Lipids And Glucose Profiles In Hyperlipidemic Subjects

Effects Of Walnut-Enriched Diet On Blood Lipids And Glucose Profiles In Hyperlipidemic Subjects: A Randomized-Controlled Trial: A Randomized-Controlled Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03680027

Enrollment

Registered

2018-09-21

Start date

2015-07-10

Completion date

2015-09-30

Last updated

2018-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidemias

Keywords

Serum lipids, Hyperlipidemia, Walnut

Brief summary

Walnuts have been shown to reduce serum lipids in hyperlipidemic individuals with a well-controlled feeding trials. Current study have been determined the effects of daily walnut consumption on serum lipids, fasting glucose and insulin levels in hyperlipidemic individuals.

Detailed description

In this, randomized controlled trial, mild to moderate hyperlipidemic subjects were randomly divided into 2 groups as walnut-enriched (n=20) and control (n=17) groups for 6 weeks. All subjects adhered to a medical nutrition therapy as low-fat and low-cholesterol diet. The walnut-enriched group was supplemented with 40 g/day of walnuts added to their diets. In order to follow nutritional status of subjects, they were visited every 15 days (in total 4 times). Anthropometric measurements of the subjects were taken and were monitored at each visit during the study. Blood samples were measured at the beginning and again at the end of the study.

Interventions

DIETARY_SUPPLEMENTWalnut-enriched Group

All subjects supplemented with 40 g/day of walnuts for 6 weeks.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

30 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Hyperlipidemic patients who are not using any lipid lowering medications * Non-smoker * No alcohol consumption * Individuals who are having ≤30kg/m2 * Individuals who do not have any allergy for nut consumption * Female participants who are not pregnant or breastfeeding * Individuals should not be in a weight loss programme * Having not consumed regular nuts for the last 1 month, * Except hypertension, they should not have other chronic diseases (such as diabetes, chronic renal failure) * No intense exercise

Exclusion criteria

* Failure to meet the criteria for inclusion criteria.

Design outcomes

Primary

Measure	Time frame	Description
Reduction in serum lipids and fasting glucose levels	Six weeks	In both group, participants have decreased serum total cholesterol and LDL-cholesterol.However especially walnut-enrcihed group significantly changed fasting glucose and insulin levels.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026